Regulatory Affairs Interview Questions and Answers

In short: These interview questions introduce common regulatory affairs terms and application pathways, with a focus on the United States, European Union, and India. Regulatory pathways and requirements vary by product and jurisdiction, so use current agency guidance and legislation when preparing a real submission.

Regulatory affairs fundamentals

1. What does regulatory affairs do in a pharmaceutical company?

Regulatory affairs coordinates communication and submissions between a company and health authorities. The work can include dossier planning, submission management, product registration, lifecycle changes, labelling, and regulatory intelligence. The exact remit depends on the organisation and markets.

2. What is the purpose of a marketing application?

A marketing application presents the evidence and product information required by a regulator to assess whether a medicine may be authorised for specified uses. Required content, format, review pathway, and decision-maker vary by jurisdiction.

3. What is the difference between an IND, NDA, and ANDA in the United States?

An Investigational New Drug application (IND) is used to request the applicable FDA exemption for shipping and administering an investigational drug in clinical studies. A New Drug Application (NDA) asks FDA to assess a drug for marketing approval. An Abbreviated New Drug Application (ANDA) is the US generic-drug pathway; it generally relies on FDA’s findings for a reference listed drug and must meet the applicable requirements, including bioequivalence where required. FDA describes these application types on its current Types of Applications page.

4. What is a generic drug product?

In the US ANDA context, the applicant seeks approval of a product that meets the applicable sameness and other statutory and regulatory requirements relative to a reference listed drug. An interview answer should not reduce generic approval to “same ingredients”: the relevant requirements depend on dosage form, route, product type, and applicable regulations.

5. What is a 505(b)(2) application?

It is a type of NDA in the United States. FDA describes it as containing full reports of investigations of safety and effectiveness where at least some information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Its use must be assessed against the proposed product and FDA’s current guidance.

6. How does an NDA differ from a 505(b)(2) application?

Both are NDA pathways under the US Federal Food, Drug, and Cosmetic Act. A traditional 505(b)(1) application relies on full reports of investigations conducted by or for the applicant, or to which the applicant has a right of reference or use. A 505(b)(2) application relies in part on information for which the applicant lacks that right. The FDA’s 2025 final guidance on choosing between an ANDA and a 505(b)(2) application should be consulted for pathway decisions.

7. What is a Drug Master File (DMF)?

A DMF is a submission that may provide FDA confidential information about facilities, processes, or articles used in making, processing, packaging, or storing human drugs. FDA states that a DMF is not itself an application for approval and is not approved or disapproved; its technical contents are reviewed in connection with a supporting application. See FDA’s Drug Master Files guidance.

8. What are the US DMF types?

FDA’s DMF guidance lists Types I to V: manufacturing site/facilities; drug substance, intermediates, or drug product; packaging material; excipient or related materials; and FDA-accepted reference information. FDA discourages Type V submissions for miscellaneous, duplicate, or misallocated information. Note that this is the older DMF framework: FDA draft DMF guidance states Type I DMFs were discontinued in 2000, so do not plan a new Type I DMF. DMFs are also expected to be submitted in electronic (eCTD) format, with Type III DMFs on a later schedule. Check FDA’s current DMF and eCTD pages (and 21 CFR 314.420) for present eligibility and submission requirements, including for Type V, before advising on a new DMF.

9. What is an Active Substance Master File (ASMF)?

An ASMF is an EU/EEA regulatory mechanism for confidential active-substance information. The applicant’s part is available to the applicant, while the restricted part remains confidential to the ASMF holder and regulator. The applicant references the file through the applicable procedure and access arrangements. Check current EMA guidance for the submission and lifecycle requirements.

10. What is the Common Technical Document (CTD)?

The ICH CTD provides a harmonised organisation for technical information in human-medicine registration applications. It has five modules: Module 1 is region-specific; Modules 2–5 cover summaries, quality, nonclinical reports, and clinical reports. Regional administrative requirements and electronic submission rules still apply. See ICH M4: CTD.

11. What is the Orange Book?

The US FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations is commonly called the Orange Book. FDA says it identifies drug products approved for safety and effectiveness and includes related patent and exclusivity information. Use the current electronic version for current entries.

12. What are the EU marketing authorisation procedures?

The EU system includes the centralised procedure and national authorisation procedures, including mutual recognition and decentralised procedures. The centralised procedure results in a Union marketing authorisation; eligibility depends on product and legal criteria. Do not assume that every application is submitted to EMA.

13. What is a Certificate of Suitability (CEP)?

A CEP is issued by the European Directorate for the Quality of Medicines & HealthCare through its certification procedure. It relates to suitability of a substance against relevant European Pharmacopoeia monographs and is used within the applicable regulatory dossier framework. Check current EDQM guidance for the substance, certificate status, and lifecycle obligations.

14. What is Hatch-Waxman, and what is a Paragraph IV certification?

The Drug Price Competition and Patent Term Restoration Act of 1984 is commonly called the Hatch-Waxman Amendments. It established the modern US generic-drug application pathway while also including patent and exclusivity provisions. Paragraph IV patent certifications and 180-day exclusivity involve specific statutory rules and case-specific conditions; consult the current statute, FDA resources, and legal advice for a live application.

15. What are the main responsibilities of a regulatory affairs professional?

Common responsibilities include maintaining regulatory plans, preparing and coordinating submissions, tracking questions and commitments, assessing changes for regulatory impact, and communicating requirements to cross-functional teams. Avoid claiming a single global procedure or universal agency structure.

Abbreviations

Related reading

Continue with Drug Regulatory Affairs and the CTD, definitions of pharmaceutical terms, and QA/QC interview questions.

Frequently asked questions

Is the CTD submission format identical in every country?

The technical CTD structure is harmonised through ICH M4, but Module 1 is regional and electronic submission requirements can differ. Check the target authority’s current instructions.

Is a DMF an approval?

No. FDA states that a DMF is not approved or disapproved as a standalone application; the information is reviewed when referenced by a supporting application.

Does an EU marketing application always go to EMA?

No. The appropriate route depends on the product and legal eligibility. EU procedures include the centralised route and national procedures such as mutual recognition and decentralised procedures.

Which products were recently approved by FDA?

“Recently approved” changes over time. Consult FDA’s current drug approval databases rather than using a static interview list. Older lists, such as the circa-2012 examples (Kalydeco, Erivedge, Inlyta, Picato, Zioptan, Surfaxin) in older versions of such lists, are historical and should not be presented as current approvals.

References

• US Food and Drug Administration. Types of Applications (current web resource, accessed 15 October 2026). FDA.
• US Food and Drug Administration. Determining Whether to Submit an ANDA or a 505(b)(2) Application, final guidance (2025). FDA guidance.
• US Food and Drug Administration. Drug Master Files: Guidelines, including 21 CFR 314.420. FDA.
• US Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), current database. FDA.
• US Food and Drug Administration. Drug Master Files Guidance for Industry (draft) and Submitting Master Files in eCTD Format, FDA.
• European Medicines Agency. Pre-authorisation guidance, current web resource (accessed 15 October 2026). EMA.
• International Council for Harmonisation. M4: The Common Technical Document, including M4(R4) organisation guideline (2016). ICH.
• European Directorate for the Quality of Medicines & HealthCare. Certification of Suitability (CEP), current web resource (accessed 15 October 2026). EDQM.
• Central Drugs Standard Control Organisation. New Drugs (New Drugs and Clinical Trials Rules, 2019). CDSCO.